The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Characterization of patients responding to enfortumab vedotin plus pembrolizumab (EV+P): exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
Gupta S, Bedke J, Van der Heijden MS, Perez Valderrama B, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Rausch S, Park SH, Drakaki A, Arafat W, Swami U, Duran I, Li J-R, Homet Moreno B, Lichfield J, Yu X, Lu Y-T, Powles TB
Enfortumab vedotin | February 27, 2026 | ASCO GU 2026
C5701003 | NCT04223856
Poster
Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC): An Exploratory Analysis in Older Patients and Those With Comorbidities From EV-302
Mar N, Gupta S, Powles T, Bedke J, Valderrama B, Kikuchi E, Hoffman-Censits J, Drakaki A, Yu E, Loriot Y, Iyer G, Vulsteke C, Jose Pablo Maroto Rey J, Swami U Park S, Homet Moreno B, Mihm M, Yu X, Lu J, van der Heijden M
Poster
Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
Gupta S, Bedke J, Van der Heijden MS, Pérez Valderrama B, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Rausch S, Park SH, Drakaki A, Arafat W, Swami U, Duran Martinez I, Li JR, Homet Moreno B, Gorla S, Yu X, Lu YT, Powles TB
Poster
EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
Bedke J, Powles T, Pérez Valderrama B, Gupta S, Kikuchi E, Loriot Y, Galsky M, Sridhar S, Yu E, Hoffman-Censits J, Iyer G, Castellano D, Pablo Maroto Rey J, Mar N, Dawson N, Bavle A, Gorla S, Yu X, Lu Y, Van der Heijden M
Presentation
EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
Thomas Powles, Michiel van der Heijden, Yohann Loriot, Jens Bedke, Begoña Pérez Valderrama, Gopakumar Iyer, Eiji Kikuchi, Jean Hoffman Censits, Christof Vulsteke, Alexandra Drakaki, Steffen Rausch, Waddah Arafat, Se Hoon Park, Umang Swami, Jian-Ri Li, Seema Gorla ,Blanca Homet Moreno , John Lu, Cindy Yu, Shilpa Gupta
Enfortumab vedotin | February 14, 2025 | ASCO GU 2025
C5701003 | NCT04223856
Presentation
EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Thomas B. Powles, Michiel Van der Heijden, Shilpa Gupta,Begoña Pérez Valderrama, Matthew D. Galsky, Jens Bedke,Eiji Kikuchi, Jean Hoffman-Censits, Jose Pablo Maroto Rey, Christof Vulsteke, Gopakumar Iyer, Umang Swami, Sang Joon Shin, Alejo Rodriguez-Vida, Michele Wozniak, Blanca Homet Moreno, Yi-Tsung Lu, Xuesong Yu, Leah Hogdal, Yohann Loriot
Enfortumab vedotin | September 15, 2024 | ESMO 2024
C5701003 | NCT04223856